{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T12:18:01Z","timestamp":1777897081376,"version":"3.51.4"},"reference-count":63,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Substance Abuse"],"published-print":{"date-parts":[[2016,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>State Medicaid policies play an important role in Medicaid enrollees\u2019 access to and use of opioid agonists, such as methadone and buprenorphine, in the treatment of opioid use disorders. Little information is available, however, regarding the evolution of state policies facilitating or hindering access to opioid agonists among Medicaid enrollees.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec sec-type=\"methods\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>During 2013\u20132014, we surveyed state Medicaid officials and other designated state substance abuse treatment specialists about their state's recent history of Medicaid coverage and policies pertaining to methadone and buprenorphine. We describe the evolution of such coverage and policies and present an overview of the Medicaid policy environment with respect to opioid agonist therapy from 2004 to 2013.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec sec-type=\"results\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among our sample of 45 states with information on buprenorphine and methadone coverage, we found a gradual trend toward adoption of coverage for opioid agonist therapies in state Medicaid agencies. In 2013, only 11% of states in our sample (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 5) had Medicaid policies that excluded coverage for methadone and buprenorphine, whereas 71% (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 32) had adopted or maintained policies to cover both buprenorphine and methadone among Medicaid enrollees. We also noted an increase in policies over the time period that may have hindered access to buprenorphine and\/or methadone.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec sec-type=\"conclusions\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>There appears to be a trend for states to enact policies increasing Medicaid coverage of opioid agonist therapies, while in recent years also enacting policies, such as prior authorization requirements, that potentially serve as barriers to opioid agonist therapy utilization. Greater empirical information about the potential benefits and potential unintended consequences of such policies can provide policymakers and others with a more informed understanding of their policy decisions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1080\/08897077.2015.1080208","type":"journal-article","created":{"date-parts":[[2015,11,13]],"date-time":"2015-11-13T20:40:25Z","timestamp":1447447225000},"page":"63-69","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":59,"title":["Policies Related to Opioid Agonist Therapy for Opioid Use Disorders: The Evolution of State Policies from 2004 to 2013"],"prefix":"10.1177","volume":"37","author":[{"given":"Rachel M.","family":"Burns","sequence":"first","affiliation":[{"name":"RAND Corporation, Pittsburgh, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosalie L.","family":"Pacula","sequence":"additional","affiliation":[{"name":"RAND Corporation, Pittsburgh, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Bauhoff","sequence":"additional","affiliation":[{"name":"RAND Corporation, Pittsburgh, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam J.","family":"Gordon","sequence":"additional","affiliation":[{"name":"University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA"},{"name":"Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hollie","family":"Hendrikson","sequence":"additional","affiliation":[{"name":"National Conference of State Legislatures, Denver, Colorado, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas L.","family":"Leslie","sequence":"additional","affiliation":[{"name":"Penn State College of Medicine, Hershey, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley D.","family":"Stein","sequence":"additional","affiliation":[{"name":"RAND Corporation, Pittsburgh, Pennsylvania, USA"},{"name":"University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2016,1,1]]},"reference":[{"key":"e_1_3_4_2_2","unstructured":"Office of Applied Studies Substance Abuse and Mental Health Services Administration. The DASIS Report. The National Survey of Substance Abuse Treatment Services (N-SSATS). Available at: http:\/\/www.oas.samhsa.gov\/2k3\/NSSATS\/NSSATS.pdf. Published 2012. Accessed June 23 2013."},{"key":"e_1_3_4_3_2","volume-title":"Drug Abuse Warning Network, 2011: National Estimates of Drug-Related Emergency Department Visits","author":"Substance Abuse and Mental Health Services Administration","year":"2013","unstructured":"Substance Abuse and Mental Health Services Administration. Drug Abuse Warning Network, 2011: National Estimates of Drug-Related Emergency Department Visits. Rockville, MD: Substance Abuse and Mental Health Administration; 2013. HHS Publication No. (SMA) 13\u20134760, DAWN Series D-39."},{"key":"e_1_3_4_4_2","unstructured":"Substance Abuse and Mental Health Services Administration. Substance use disorders. Available at: http:\/\/www.samhsa.gov\/disorders\/substance-use. 2014; Accessed March 17 2015."},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055255"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022164"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200523010-00007"},{"issue":"3","key":"e_1_3_4_8_2","first-page":"CD002209","article-title":"Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence","author":"Mattick RP","year":"2009","unstructured":"Mattick RP, , Breen C, , Kimber J, , Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009;(3):CD002209.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_4_9_2","volume-title":"Methadone Maintenance Program and Patient Census in the US","author":"American Methadone Treatment Association","year":"1998","unstructured":"American Methadone Treatment Association. Methadone Maintenance Program and Patient Census in the US. New York: American Methadone Treatment Association; 1998."},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2009.07.013"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.300.1.jrr80005"},{"key":"e_1_3_4_12_2","volume-title":"The N-SSATS Report: Trends in the Use of Methadone and Buprenorphine at Substance Abuse Treatment Facilities: 2003 to 2011","author":"Substance Abuse and Mental Health Services Administration","year":"2013","unstructured":"Substance Abuse and Mental Health Services Administration. The N-SSATS Report: Trends in the Use of Methadone and Buprenorphine at Substance Abuse Treatment Facilities: 2003 to 2011. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2013."},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1300\/J069v18n02_02"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.1.102"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2009.02539.x"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.2001.96912676.x"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.3310\/hta11090"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(03)00169-8"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-011-0222-2"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1081\/JA-120004176"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2010.0532"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1080\/10826080802483936"},{"key":"e_1_3_4_23_2","unstructured":"H.R. 4365\u2014106th Congress. Drug Addiction Treatment Act of 2000 2000."},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1186\/1747-597X-3-17"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(03)00061-9"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2012.1065"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.201200298"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1402780"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1023\/B:APIH.0000003017.78877.56"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2011.02.002"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2007.11.018"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02287379"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11414-006-9018-2"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/1468-0009.00139"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.201100034"},{"key":"e_1_3_4_36_2","first-page":"9","volume-title":"Advancing Access to Addiction Medications: Implications for Opioid Addiction Treatment","author":"Rinaldo SG","year":"2013","unstructured":"Rinaldo SG, , Rinaldo DW. Availability without accessibility? State Medicaid coverage and authorization requirements for opioid dependence medications: implications for opioid addiction treatment. In: Advancing Access to Addiction Medications: Implications for Opioid Addiction Treatment. Chevy Chase, MD: American Society of Addiction Medicine, The Avisa Group; 2013:9\u201360."},{"key":"e_1_3_4_37_2","doi-asserted-by":"crossref","unstructured":"Dick AW Pacula RL Gordon AJ Sorbero M Burns RM Leslie D Stein BD. Growth in buprenorphine waivers for physicians increased potential access to opioid agonist treatment 2002\u201311. Health Aff. 2015;34:1028\u20131034.","DOI":"10.1377\/hlthaff.2014.1205"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2011.06.005"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2012.0294"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1300\/J069v19n03_02"},{"key":"e_1_3_4_41_2","unstructured":"Research and Policy Analysis Group of Carnevale Associates LLC. Information brief\u2013The Affordable Care Act: Shaping substance abuse treatment. Webinar; 2013. https:\/\/www.medicaid.gov\/medicaid-chip-program-information\/by-topics\/benefits\/downloads\/sud-services-webinar.pdf. Accessed February 17 2016."},{"key":"e_1_3_4_42_2","volume-title":"Coverage and Delivery of Adult Substance Abuse Services in Medicaid Managed Care","author":"Boozang P","year":"2014","unstructured":"Boozang P, , Bachrach D, , Detty A. Coverage and Delivery of Adult Substance Abuse Services in Medicaid Managed Care. Washington, DC: Centers for Medicare & Medicaid Services; 2014."},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1111\/add.12208"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61331-7"},{"issue":"2","key":"e_1_3_4_45_2","first-page":"CD002207","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","author":"Mattick RP","year":"2014","unstructured":"Mattick RP, , Breen C, , Kimber J, , Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;2:CD002207.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_4_46_2","volume-title":"Principles of Effective Treatment for Criminal Justice Populations","author":"National Institute on Drug Abuse","year":"2006","unstructured":"National Institute on Drug Abuse. Principles of Effective Treatment for Criminal Justice Populations. Rockville, MD: National Institute on Drug Abuse; 2006."},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-011-1962-8"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2011.10.016"},{"key":"e_1_3_4_49_2","unstructured":"Office of National Drug Control Policy. Reauthorization Act of 2006 (ONDCPRA) 2006."},{"key":"e_1_3_4_50_2","first-page":"1964","article-title":"The impact of prior authorization on buprenorphine dose, relapse rates, and cost for Massachusetts Medicaid beneficiaries with opioid dependence","volume":"49","author":"Clark RE","year":"2014","unstructured":"Clark RE, , Baxter JD, , Barton BA, , Aweh G, , O'Connell E, , Fisher WH. The impact of prior authorization on buprenorphine dose, relapse rates, and cost for Massachusetts Medicaid beneficiaries with opioid dependence. Health Serv Res. 2014;49:1964\u20131979.","journal-title":"Health Serv Res"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2014-0840"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2012-1342"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.2174\/157488611794480034"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1097\/PCC.0b013e3181f3a118"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2014.06.005"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2011.07.019"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2011.09.029"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2014.02.003"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0b013e3181bd4c10"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0b013e3181734a77"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2011.0480"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2014.07.010"},{"key":"e_1_3_4_63_2","unstructured":"Bauhoff S Stein BD Pacula RL . Do substance abuse policies influence opioid agonist therapies in substance abuse treatment facilities? Paper presented at the Addiction Health Services Research Conference; October 15\u201317 2014; Boston MA."},{"key":"e_1_3_4_64_2","unstructured":"American Society of Addiction Medicine. State Medicaid reports. http:\/\/www.asam.org\/advocacy\/aaam\/state-medicaid-reports. Accessed January 22 2015."}],"container-title":["Substance Abuse"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1080\/08897077.2015.1080208","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1080\/08897077.2015.1080208","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1080\/08897077.2015.1080208","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T08:46:35Z","timestamp":1777625195000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1080\/08897077.2015.1080208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["10.1080\/08897077.2015.1080208"],"URL":"https:\/\/doi.org\/10.1080\/08897077.2015.1080208","relation":{},"ISSN":["0889-7077","1547-0164"],"issn-type":[{"value":"0889-7077","type":"print"},{"value":"1547-0164","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1]]}}}